---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011585"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:10:08.828641+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Q2 net loss $0.42/shr; expects MAD Phase 1 topline for GT-02287 in August 2024

## Summary
- Net loss per share $0.42 for Q2 2024 vs $0.62 in Q2 2023; cash & securities $16.9M as of June 30, 2024.
- Topline results from MAD Phase 1 study of GT-02287 for Parkinson's disease expected in August 2024.
- Phase 1b study in Parkinson's patients with/without GBA1 mutation initiation anticipated in Q4 2024.
- Gene Mack appointed interim CEO and CFO; Khalid Islam serves as Executive Chairman.
- Completed underwritten public offering with approximately $10.0M net proceeds.

## SEC filing metadata
- accession: 0001558370-24-011585
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837024011585/0001558370-24-011585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837024011585/ganx-20240808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011585
- JSON: https://secwatch.observer/filing/0001558370-24-011585.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011585.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.